JPWO2021055349A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021055349A5 JPWO2021055349A5 JP2022517339A JP2022517339A JPWO2021055349A5 JP WO2021055349 A5 JPWO2021055349 A5 JP WO2021055349A5 JP 2022517339 A JP2022517339 A JP 2022517339A JP 2022517339 A JP2022517339 A JP 2022517339A JP WO2021055349 A5 JPWO2021055349 A5 JP WO2021055349A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cell
- cells
- expression construct
- scfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962902237P | 2019-09-18 | 2019-09-18 | |
| US62/902,237 | 2019-09-18 | ||
| PCT/US2020/050864 WO2021055349A1 (en) | 2019-09-18 | 2020-09-15 | A method of engineering natural killer-cells to target bcma-positive tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548902A JP2022548902A (ja) | 2022-11-22 |
| JPWO2021055349A5 true JPWO2021055349A5 (https=) | 2023-09-29 |
| JP2022548902A5 JP2022548902A5 (https=) | 2023-09-29 |
Family
ID=74883668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517339A Pending JP2022548902A (ja) | 2019-09-18 | 2020-09-15 | Ｂｃｍａ陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220370500A1 (https=) |
| EP (1) | EP4031577A4 (https=) |
| JP (1) | JP2022548902A (https=) |
| CN (1) | CN114729046A (https=) |
| AR (1) | AR119990A1 (https=) |
| TW (1) | TW202124447A (https=) |
| WO (1) | WO2021055349A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| KR20240021179A (ko) * | 2021-05-14 | 2024-02-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 폴리펩티드 및 사용 방법 |
| CN118265535A (zh) * | 2021-10-20 | 2024-06-28 | 得克萨斯大学体系董事会 | 具有最佳信号传导的car构建体的工程化nk细胞 |
| KR20240099161A (ko) | 2021-10-20 | 2024-06-28 | 다케다 야쿠힌 고교 가부시키가이샤 | Bcma를 표적화하는 조성물 및 이의 사용 방법 |
| WO2023177954A1 (en) * | 2022-03-18 | 2023-09-21 | University Of Rochester | Combination therapy for treatment of cancer, methods and systems of delivery thereof |
| JP2026512487A (ja) * | 2023-04-18 | 2026-04-16 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｂｃｍａキメラ抗原受容体及びその使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA033110B1 (ru) * | 2012-04-11 | 2019-08-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы |
| EA036379B1 (ru) * | 2014-12-12 | 2020-11-02 | Блубёрд Био, Инк. | Химерные антигенные рецепторы к bcma |
| EP3283520B1 (en) * | 2015-04-13 | 2020-05-06 | Pfizer Inc | Chimeric antigen receptors targeting b-cell maturation antigen |
| TWI833684B (zh) * | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體（ｃａｒ）、組合物及其使用方法 |
| WO2018195339A1 (en) * | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| US11905528B2 (en) * | 2017-10-12 | 2024-02-20 | Icell Gene Therapeutics Inc. | Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof |
| CN109468283A (zh) * | 2018-11-30 | 2019-03-15 | 北京美康基免生物科技有限公司 | 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
| CN109734814A (zh) * | 2019-02-12 | 2019-05-10 | 南京卡提医学科技有限公司 | 具有免疫受体的工程化t细胞治疗癌症的用途 |
-
2020
- 2020-09-15 US US17/761,190 patent/US20220370500A1/en not_active Abandoned
- 2020-09-15 WO PCT/US2020/050864 patent/WO2021055349A1/en not_active Ceased
- 2020-09-15 EP EP20866895.4A patent/EP4031577A4/en not_active Withdrawn
- 2020-09-15 JP JP2022517339A patent/JP2022548902A/ja active Pending
- 2020-09-15 CN CN202080079943.1A patent/CN114729046A/zh active Pending
- 2020-09-17 AR ARP200102578A patent/AR119990A1/es unknown
- 2020-09-18 TW TW109132239A patent/TW202124447A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2945308C (en) | Transgene genetic tags and methods of use | |
| JP2022184852A5 (https=) | ||
| AU2016342560B2 (en) | Receptor | |
| EP3564266A1 (en) | Novel chimeric antigen receptor and use thereof | |
| CN109280086B (zh) | 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体 | |
| JP6990244B2 (ja) | ヒトｃｄ１２３を標的とするキメラ受容体リガンド及びその応用 | |
| CN111417652A (zh) | 嵌合多肽及其用途 | |
| AU2018321134B2 (en) | Chimeric antigen receptor and CAR-T cells that bind CXCR5 | |
| CN111479918A (zh) | 细胞 | |
| KR20210018838A (ko) | 유전자 조작된 세포 및 응용 | |
| JPWO2021071962A5 (https=) | ||
| WO2023193660A1 (zh) | 增强型嵌合抗原受体及其应用 | |
| CN113874391A (zh) | 靶向baff-r/cd19的嵌合抗原受体修饰的t细胞及其用途 | |
| JP2023540551A (ja) | 免疫療法組成物 | |
| CN120035658A (zh) | Nkg2d工程化细胞及其组合物 | |
| KR20210111244A (ko) | 태반-유래 동종이계 car-t 세포 및 이의 용도 | |
| JPWO2020117526A5 (https=) | ||
| JPWO2021055349A5 (https=) | ||
| CN112300288B (zh) | 一种cik细胞的嵌合抗原受体car及其应用 | |
| WO2021183755A1 (en) | Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment | |
| JPWO2022216624A5 (https=) | ||
| JPWO2021142127A5 (https=) | ||
| JPWO2022098914A5 (https=) | ||
| JPWO2023278520A5 (https=) | ||
| JPWO2023283644A5 (https=) |